BREXPIPRAZOLE (brexpiprazole) by Hetero is unknown. Approved for schizophrenia. First approved in 2023.
Drug data last refreshed 19h ago
unknown. However, the efficacy of brexpiprazole may be mediated through a combination of partial agonist activity at serotonin 5-HT 1A and dopamine D 2 receptors, and antagonist activity at serotonin 5-HT 2A receptors.
Atypical Antipsychotic
Food Effect Study of Brexpiprazole Once-weekly (QW) Formulation in Patients With Schizophrenia
Real-life Assessment of Brexpiprazole (Rexulti) in Schizophrenia and in Depressive Disorders
A Trial to Assess the Effects of Prazosin or Propranolol on Blood Pressure in the Presence of Brexpiprazole/Sertraline
Open-label Brexpiprazole fMRI Trial in Adults With Major Depressive Disorder and Anxiety
Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Schizophrenia
Worked on BREXPIPRAZOLE at Hetero? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.